Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1987 5
1988 11
1989 10
1990 9
1991 6
1992 12
1993 10
1994 9
1995 11
1996 10
1997 19
1998 15
1999 16
2000 12
2001 9
2002 9
2003 14
2004 18
2005 10
2006 19
2007 20
2008 22
2009 25
2010 19
2011 16
2012 18
2013 30
2014 33
2015 40
2016 51
2017 44
2018 60
2019 56
2020 64
2021 72
2022 55
Text availability
Article attribute
Article type
Publication date

Search Results

772 results
Results by year
Filters applied: . Clear all
Page 1
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. Singh S, et al. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6. doi: 10.1016/j.cgh.2020.01.008. Epub 2020 Jan 13. Clin Gastroenterol Hepatol. 2020. PMID: 31945470 Free PMC article. Review.
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naive) and second-line (prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moderate to severely active ulcerative colitis in a systematic rev …
BACKGROUND & AIMS: We compared the efficacy and safety of different first-line (biologic-naive) and second-line (prior exposure to tumor …
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Feagan BG, et al. Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. Lancet. 2021. PMID: 34090625 Clinical Trial.
BACKGROUND: The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. ...INTERPRETATION: Filgotinib 200 mg was well tolerated, and efficacious in inducing and maintaining clinical remission c …
BACKGROUND: The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial …
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. Salas A, et al. Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):323-337. doi: 10.1038/s41575-020-0273-0. Epub 2020 Mar 19. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32203403 Review.
The biological effects of cytokines, including several involved in the pathology of Crohn's disease and ulcerative colitis, occur as a result of receptor-mediated signalling through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) D …
The biological effects of cytokines, including several involved in the pathology of Crohn's disease and ulcerative colitis, oc …
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J, Farraye FA, Kiran RP, Fleshner P, Rosh J, Shah SA, Chang S, Scherl E, Pardi DS, Schwartz DA, Kotze PG, Bruining DH, Kane SV, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, McCormick JT, Picoraro JA, Silverberg MS, Bernstein CN, Sandborn WJ, Vermeire S. Shen B, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):826-849. doi: 10.1016/S2468-1253(21)00101-1. Epub 2021 Aug 18. Lancet Gastroenterol Hepatol. 2021. PMID: 34416186 Review.
Restorative proctocolectomy with ileal pouch-anal anastomosis is an option for most patients with ulcerative colitis or familial adenomatous polyposis who require colectomy. ...
Restorative proctocolectomy with ileal pouch-anal anastomosis is an option for most patients with ulcerative colitis or famili …
Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases.
Barnes EL, Loftus EV Jr, Kappelman MD. Barnes EL, et al. Gastroenterology. 2021 Feb;160(3):677-689. doi: 10.1053/j.gastro.2020.08.064. Epub 2020 Oct 21. Gastroenterology. 2021. PMID: 33098884 Review.
Although Crohn's disease (CD) and ulcerative colitis (UC) have been considered as disorders that affect individuals of European ancestry, the epidemiology of the inflammatory bowel diseases (IBDs) is changing. ...
Although Crohn's disease (CD) and ulcerative colitis (UC) have been considered as disorders that affect individuals of Europea …
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Peyrin-Biroulet L, et al. Gastroenterology. 2021 Oct;161(4):1156-1167.e3. doi: 10.1053/j.gastro.2021.06.015. Epub 2021 Jun 16. Gastroenterology. 2021. PMID: 34144047 Free article. Clinical Trial.
BACKGROUND AND AIMS: VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis
BACKGROUND AND AIMS: VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Parti …
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
Singh S, Feuerstein JD, Binion DG, Tremaine WJ. Singh S, et al. Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18. Gastroenterology. 2019. PMID: 30576642 Free PMC article. Review.
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed by primary care physicians or gastroenterologists. ...Focused questions included the following: (1) comparative effectiveness and tolerabil …
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed …
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S, Fumery M, Sandborn WJ, Murad MH. Singh S, et al. Aliment Pharmacol Ther. 2018 Jan;47(2):162-175. doi: 10.1111/apt.14422. Epub 2017 Dec 4. Aliment Pharmacol Ther. 2018. PMID: 29205406 Review.
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: To assess comparative efficacy and safety of different therapies as first-line (biologic-naive) and second-line (prior exposure to anti-tumo …
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: …
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.
Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. Sandborn WJ, et al. J Crohns Colitis. 2020 Sep 16;14(9):1202-1213. doi: 10.1093/ecco-jcc/jjaa049. J Crohns Colitis. 2020. PMID: 32161949 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities. We describe preclinical to clinical translation of TD-1473-an oral gut-selective pan-JAK inhibitor-from in vitro characterizat …
BACKGROUND AND AIMS: Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited b …
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV, Panes J, Danese S. Ghosh S, et al. J Crohns Colitis. 2021 Dec 18;15(12):2022-2030. doi: 10.1093/ecco-jcc/jjab099. J Crohns Colitis. 2021. PMID: 34107013 Free PMC article. Clinical Trial.
BACKGROUND AND AIMS: Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not commonly assessed in clinical trials. ...METHODS: Patients aged 18-75 years, with moderately to severely active ulcerative coliti
BACKGROUND AND AIMS: Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not …
772 results